Compositions and methods for treating epigenetic disease
Patent: WO2020023333A1
Abstract: The present disclosure provides compounds and compositions capable of treating cancer or an autoimmune disease, such as Crohn’s disease, and methods of use thereof.
Applicant: University of California, Los Angeles (UCLA)
Inventors: Dimitrios Iliopoulos, Michael Jung, Jonghoon Kim, Jill Hoffman, Iordanes Karagiannides
LIN28-MEDIATED CONTROL OF LET-7 BIOGENESIS
Publication number: 20140328858
Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3’ terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
Type: Application
Filed: May 2, 2014
Publication date: November 6, 2014
Applicants: Children’s Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER AND PROGRESSION, AND FOR SCREENING ANTI-CANCER AGENTS
Patent number: 8617818
Abstract: MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGFb-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1?/? mice exhibited increased invasiveness because of EMT induced by miR-200 downregulation. EMT was found to be controlled by miRNA species that are regulated by the balance between Akt1 and Akt2, rather than overall Akt levels.
Type: Grant
Filed: September 30, 2011
Date of Patent: December 31, 2013
Assignees: Tufts Medical Center, President and Fellows of Harvard College
Inventors: Philip N. Tsichlis, Christos Polytarchou, Dimitrios Iliopoulos
USE OF METFORMIN IN CANCER TREATMENT AND PREVENTION
Publication number: 20120220664
Abstract: Disclosed herein is a method for treating a tumor in a subject in need thereof comprising administering an enhancing amount of metformin and a reduced amount of one or more chemotherapeutic agents. One example of an enhancing amount of metformin is about 250 mg/day. Also disclosed is a Untreated method for preventing cancer or delaying the recurrence of cancer in a subject comprising administering an effective amount of metformin to the subject. In one example of such a method, the amount of metformin is about 75 mg/day. Also disclosed is a composition comprising an enhancing amount of metformin, and a reduced amount of one or more chemotherapeutic agents and a pharmaceutically acceptable carrier. Kits comprising metformin and one or more chemotherapeutic agents are also disclosed.
Type: Application
Filed: August 25, 2010
Publication date: August 30, 2012
Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors: Kevin Struhl, Heather Hirsch, Dimitrios Iliopoulos
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER AND PROGRESSION, AND FOR SCREENING ANTI-CANCER AGENTS
Publication number: 20120021983
Abstract: MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGF?-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1-/- mice exhibited increased invasiveness because of EMT induced by miR-200 downregulation. EMT was found to be controlled by miRNA species that are regulated by the balance between Akt1 and Akt2, rather than overall Akt levels.
Type: Application
Filed: September 30, 2011
Publication date: January 26, 2012
Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, TUFTS MEDICAL CENTER, INC.
Inventors: Philip N. Tsichlis, Christos Polytarchou, Dimitrios Iliopoulos
NEUROTENSIN-INDUCED TUMOR FORMATION IS REGULATED BY MICRORNA 133A-AFTIPHILIN-DEPENDENT RECEPTOR RECYCLING
Publication number: 62877902
Abstract: MiR-133a was found to be up-regulated in colonic biopsies from patients with ulcerative colitis. A chemical inhibitor of miR-133a expression blocked miR-133a expression levels and reduced substantially colitis in mice.
Type: Application
Filed: October 10, 2014
Applicants: UNIVERSITY OF CALIFORNIA LOS ANGELES
Inventors: Charalabos Pothoulakis, Ivy K Law, Dimitrios Iliopoulos
MIR-214 AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER SPECIFIC FOR ULCERATIVE COLITIS AND A MIR-214 INHIBITOR FOR TREATMENT OF SAME
Publication number: 62877902
Abstract: MiR-214 was found to be up-regulated in colonic biopsies from patients with ulcerative colitis. A chemical inhibitor of miR-214 expression blocked miR-214 expression levels and reduced substantially colitis in mice.
Type: Application
Filed: December 10, 2015
Applicants: UNIVERSITY OF CALIFORNIA LOS ANGELES
Inventors: Dimitrios Iliopoulos